Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals

被引：0
|
作者：
Alison R Meloni
Mary Beth DeYoung
Jenny Han
Jennie H Best
Michael Grimm
机构：
[1] Amylin Pharmaceuticals,
[2] LLC,undefined
来源：
Cardiovascular Diabetology | / 12卷
关键词：
Number needed to treat; Absolute benefit; Exenatide; Type 2 diabetes; Diabetes mellitus; ADA treatment guidelines; GLP-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Exenatide Once Weekly for the Treatment of Type 2 Diabetes Mellitus: Clinical Results in Subgroups of Patients Using Different Concomitant Medications
    Pencek, Richard
    Brunell, Steven C.
    Li, Yan
    Hoogwerf, Byron J.
    Malone, James
    POSTGRADUATE MEDICINE, 2012, 124 (04) : 33 - 40
  • [32] Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial
    Arakaki, R. F.
    Blevins, T. C.
    Wise, J. K.
    Liljenquist, D. R.
    Jiang, H. H.
    Jacobson, J. G.
    Martin, S. A.
    Jackson, J. A.
    DIABETES OBESITY & METABOLISM, 2014, 16 (06): : 510 - 518
  • [33] PROJECTED COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY VERSUS EXENATIDE BID FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UK
    Wilson, B. P.
    Beaudet, A.
    Caputo, J.
    Timlin, L.
    VALUE IN HEALTH, 2011, 14 (07) : A476 - A476
  • [34] The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus
    Wang, Jie
    Li, Hui-qin
    Xu, Xiao-hua
    Kong, Xiao-cen
    Sun, Rui
    Jing, Ting
    Ye, Lei
    Su, Xiao-fei
    Ma, Jian-hua
    BIOMED RESEARCH INTERNATIONAL, 2019, 2019
  • [35] Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
    Sukhareva, O. Y.
    Shestakova, M., V
    DIABETES MELLITUS, 2016, 19 (01): : 72 - 79
  • [36] Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial
    Heine, RJ
    Van Gaal, LF
    Johns, D
    Mihm, MJ
    Widel, MH
    Brodows, RG
    ANNALS OF INTERNAL MEDICINE, 2005, 143 (08) : 559 - 569
  • [37] Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes: an update
    Tomlinson, Brian
    Chan, Paul
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (04) : 175 - 179
  • [38] Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy
    Karagianni, P.
    Polyzos, S. A.
    Kartali, N.
    Zografou, I
    Sambanis, C.
    ADVANCES IN MEDICAL SCIENCES, 2013, 58 (01): : 38 - 43
  • [39] Exenatide once weekly results in significantly greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes
    Drucker, Daniel J.
    Buse, John B.
    Taylor, Kristin
    Kendall, David
    Trautmann, Michael
    Zhuang, Dongliang
    Porter, Lisa
    DIABETES, 2008, 57 : A33 - A33
  • [40] Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
    Lawrence Blonde
    Richard Pencek
    Leigh MacConell
    Cardiovascular Diabetology, 14
12345